OBJECTIVE: We investigated risk factors for Type II (n = 176) vs. Type I (n = 1,576) endometrial cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008. METHODS: Clinical data were available from the University of Pittsburgh Medical Center (UPMC) Network Cancer Registry. Logistic regression was used to estimate the adjusted odds of having Type II EC vs. Type I EC. Risk factors of interest in this analysis were age, race, body mass index (BMI), year of diagnosis, parity, menopausal status, and history of additional primary tumors. RESULTS: Relative to women with Type I EC, women with Type II EC were more likely to be older at diagnosis (OR: 1.03 per 1 year increase in age, 95% CI 1.01-1.05), of non-white race (OR: 2.95, 95% CI 1.66-5.27), have a history of additional primary tumors (OR: 1.56, 95% CI 1.05-2.32), and less likely to be obese (OR: 0.45, 95% CI 0.29-0.70). CONCLUSION: In this large retrospective cohort of patients with EC, the striking difference in risk factors associated with Type II vs. Type I tumors suggests that these subtypes represent different disease entities that require different treatment modalities. Currently, Type II cases have a significantly worse prognosis compared to Type I. Further characterization of risk factors associated with developing Type II tumors is needed to prevent this aggressive malignancy.
OBJECTIVE: We investigated risk factors for Type II (n = 176) vs. Type I (n = 1,576) endometrial cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008. METHODS: Clinical data were available from the University of Pittsburgh Medical Center (UPMC) Network Cancer Registry. Logistic regression was used to estimate the adjusted odds of having Type II EC vs. Type I EC. Risk factors of interest in this analysis were age, race, body mass index (BMI), year of diagnosis, parity, menopausal status, and history of additional primary tumors. RESULTS: Relative to women with Type I EC, women with Type II EC were more likely to be older at diagnosis (OR: 1.03 per 1 year increase in age, 95% CI 1.01-1.05), of non-white race (OR: 2.95, 95% CI 1.66-5.27), have a history of additional primary tumors (OR: 1.56, 95% CI 1.05-2.32), and less likely to be obese (OR: 0.45, 95% CI 0.29-0.70). CONCLUSION: In this large retrospective cohort of patients with EC, the striking difference in risk factors associated with Type II vs. Type I tumors suggests that these subtypes represent different disease entities that require different treatment modalities. Currently, Type II cases have a significantly worse prognosis compared to Type I. Further characterization of risk factors associated with developing Type II tumors is needed to prevent this aggressive malignancy.
Authors: F D Cirisano; S J Robboy; R K Dodge; R C Bentley; H R Krigman; I S Synan; J T Soper; D L Clarke-Pearson Journal: Gynecol Oncol Date: 1999-09 Impact factor: 5.482
Authors: David M Boruta; Paola A Gehrig; Pamela A Groben; Victoria Bae-Jump; John F Boggess; Wesley C Fowler; Linda Van Le Journal: Cancer Date: 2004-11-15 Impact factor: 6.860
Authors: Robert A Soslow; John P Bissonnette; Andrew Wilton; Sarah E Ferguson; Kaled M Alektiar; Linda R Duska; Esther Oliva Journal: Am J Surg Pathol Date: 2007-07 Impact factor: 6.394
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Deborah F DeLair; Kathleen A Burke; Pier Selenica; Raymond S Lim; Sasinya N Scott; Sumit Middha; Abhinita S Mohanty; Donavan T Cheng; Michael F Berger; Robert A Soslow; Britta Weigelt Journal: J Pathol Date: 2017-09-05 Impact factor: 7.996
Authors: Theodore M Brasky; Todd R Sponholtz; Julie R Palmer; Lynn Rosenberg; Edward A Ruiz-Narváez; Lauren A Wise Journal: Am J Epidemiol Date: 2016-01-10 Impact factor: 4.897
Authors: Britton Trabert; Nicolas Wentzensen; Ashley S Felix; Hannah P Yang; Mark E Sherman; Louise A Brinton Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01 Impact factor: 4.254
Authors: Ashley S Felix; David E Cohn; Theodore M Brasky; Richard Zaino; Kay Park; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Marcus E Randall; Louise A Brinton Journal: Am J Obstet Gynecol Date: 2018-08-07 Impact factor: 8.661
Authors: Louise A Brinton; Britton Trabert; Garnet L Anderson; Roni T Falk; Ashley S Felix; Barbara J Fuhrman; Margery L Gass; Lewis H Kuller; Ruth M Pfeiffer; Thomas E Rohan; Howard D Strickler; Xia Xu; Nicolas Wentzensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-04-12 Impact factor: 4.254
Authors: Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino Journal: Gynecol Oncol Date: 2013-02-26 Impact factor: 5.482
Authors: Ernest K Amankwah; Christine M Friedenreich; Anthony M Magliocco; Rollin Brant; Kerry S Courneya; Thomas Speidel; Wahida Rahman; Annie R Langley; Linda S Cook Journal: Am J Epidemiol Date: 2013-05-14 Impact factor: 4.897